Pharmafile Logo
Pharmafocus logo
Advanced Search

Daiichi Sankyo

Showing 15 posts of 59 posts found.

shutterstock_273326141

AstraZeneca partners with Daichii Sankyo in potential $6bn cancer drug deal

July 27, 2020
Research and Development, Sales and Marketing AstraZeneca, Daiichi Sankyo, partnership, pharma

AstraZeneca and Daiichi Sankyo have joined forces to drive the development and commercialisation of the latter’s DS-1062, a trophoblast cell-surface …

News
index_ph001

Daiichi Sankyo’s Turalio becomes first FDA-approved therapy for rare tumour

August 5, 2019
Sales and Marketing Cancer, Daiichi Sankyo, FDA, Turalio, US, pharma, rare cancer

Daiichi Sankyo has seen its CSF1R inhibitor Turalio (pexidartinib) approved by the FDA in the treatment of symptomatic tenosynovial giant …

News
index_ph001

Two Daiichi Sankyo drugs dealt a thumbs up and thumbs down by FDA advisory panel

May 15, 2019
Research and Development, Sales and Marketing Daiichi Sankyo, FDA, pexidartinib, pharma, quizartinib

Daiichi Sankyo was left with a bittersweet taste in its mouth after it saw one of its drugs recommended for …

News
shutterstock_273326141

AstraZeneca and Daiichi Sankyo partner up for $6.9 billion cancer collaboration

March 29, 2019
Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Cancer, Daiichi Sankyo, pharma

AstraZeneca and Daiichi Sankyo have announced a new collaboration agreement to the tune of potentially $6.9 billion which will see …

News
index_ph001

Daiichi Sankyo show positive results for atrial fibrillation treatment Lixiana

March 18, 2019
Manufacturing and Production, Research and Development Daiichi Sankyo, Lixiana, pharma, vitamin K antagonist

Japanese firm Daiichi Sankyo has announced positive results of the first randomised controlled trial of uninterrupted Lixiana (edoxoban) in atrial …

News
daiichi-sankyo-us

Daiichi Sankyo: Two steps forward, one step back in cancer deals

December 14, 2017
Sales and Marketing Daiichi Sankyo, biotech, drugs, pharma, pharmaceutical

Daiichi Sankyo had a busy day in terms of its deals in oncology, not only did it tear up its …

News
daiichi_sankyo_1_0

Daiichi settles undisclosed drug side-effects case for $300 million

August 2, 2017
Research and Development, Sales and Marketing Benicar, Daiichi Sankyo, biotech, drugs, pharma, pharmaceutical

Daiichi Sankyo has settled a case alleging that it did not fully disclose adverse side-effects of its drug, Benicar, with …

News
index_ph001

Big success and even bigger failure for Daiichi Sankyo’s experimental therapy

July 3, 2017
Research and Development, Sales and Marketing Daiichi Sankyo, mirogabalin

Daiichi Sankyo has been hit with mixed news this week regarding its experimental therapy mirogabalin. The drug posted trial success …

News
index_ph001

Daiichi pulls out of India with closure of 170-strong R&D plant

January 11, 2017
Manufacturing and Production, Research and Development Daiichi Sankyo, Ranbaxy, Sun Pharma

Japanese pharma firm Daiichi Sankyo has announced its intention to close its R&D centre in Gurgaon, India, a step in …

News
handshake

Amgen agrees deal to commercialise biosimilars in Japan with Daiichi Sankyo

July 14, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Amgen, Daiichi Sankyo, Japan, biosimilars

Amgen (NASDAQ: AMGN) has agreed a deal with Daiichi Sankyo (TSE: 4568) that will see the pair commercialise nine biosimilars …

News

UCB scores Japanese approval for seizure therapy, Vimpat

July 5, 2016
Manufacturing and Production, Research and Development Daiichi Sankyo, Japan, UCB, japanese

UCB Biopharma (EURONEXT: UCB) and Daiichi Sankyo have announced that Vimpat (lacosamide) has been approved as an adjunctive therapy in …

News
celltherapy

Cell Therapy signs £12.5 million licensing deal with Daiichi Sankyo for heart failure treatment

May 10, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Daiichi Sankyo, Deals, cell therapy, heart failure, licensing

UK-based Cell Therapy on Tuesday said it has signed a £12.5 million licensing deal with Japan’s Daiichi Sankyo (TYO: 4568) …

News
index_ph001

Daiichi Sankyo names Antoine Yver global head of oncology research and development

April 1, 2016
Business Services, Medical Communications Daiichi Sankyo, Japan, appointment

Japanese drug major Daiichi Sankyo (TYO: 4568) on Friday named Antoine Yver, global head, oncology research and development, effective April …

Appointment
Daiichi Sankyo researchers

Daiichi Sankyo to expand access to clinical trial data

February 3, 2016
Research and Development Daiichi Sankyo, R&D, clinical trials, open access, open data, transparency

Daiichi Sankyo has announced today that it will share clinical trial data to qualified researchers through an online web request …

News
sign-web

Daiichi Sankyo rocked by further job losses

December 9, 2015
Manufacturing and Production Daiichi, Daiichi Sankyo

The Japanese pharma firm Daiichi Sankyo is to close an antibody-producing subsidiary in Germany, as the company continues to cut …

Appointment
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025